Serum soluble Fas in the syndrome of hemolysis, elevated liver enzymes, and low platelets

Hassan Harirah, Sahar E. Donia, Chaur Dong Hsu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

OBJECTIVE: To assess whether serum levels of soluble Fas and soluble Fas ligand are altered in the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). METHODS: Serum samples from 22 pregnant women diagnosed with HELLP syndrome were compared with sera from 37 healthy women with noncomplicated singleton pregnancies. Serum levels of soluble Fas and soluble Fas ligands were determined by enzyme immunoassay. Student t, χ2, Pearson's correlation coefficient, and multiple regression tests were used for statistical analyses. RESULTS: Both soluble Fas and soluble Fas ligand were detected in the sera of normal pregnancies as well as in those with HELLP syndrome. The mean serum level of soluble Fas was significantly higher in women with HELLP syndrome than in healthy gravidas (10.75 ± 0.93 versus 5.81 ± 0.37 U/mL, P < .001). However, there was no significant difference in mean serum soluble Fas ligand levels of the two groups (0.60 ± 0.06 compared with 0.50 ± 0.22 ng/mL, P = .23). In women with HELLP syndrome, there were no significant correlations between serum levels of soluble Fas or soluble Fas ligand with liver transaminases (aspartate and alanine aminotransferase) and platelet count. CONCLUSION: Serum levels of soluble Fas, but not soluble Fas ligand, are significantly higher in women with HELLP syndrome than healthy gravidas. The source of elevated serum levels of soluble Fas in HELLP syndrome remains to be determined.

Original languageEnglish (US)
Pages (from-to)295-298
Number of pages4
JournalObstetrics and Gynecology
Volume98
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Hemolysis
Blood Platelets
Fas Ligand Protein
Liver
Enzymes
Serum
Pyridinolcarbamate
Pregnancy
Aspartate Aminotransferases
Transaminases
Alanine Transaminase
Immunoenzyme Techniques
Platelet Count
Pregnant Women
Students

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Serum soluble Fas in the syndrome of hemolysis, elevated liver enzymes, and low platelets. / Harirah, Hassan; Donia, Sahar E.; Hsu, Chaur Dong.

In: Obstetrics and Gynecology, Vol. 98, No. 2, 2001, p. 295-298.

Research output: Contribution to journalArticle

@article{9cf8c44d368c4f0594a70cd6aefed8df,
title = "Serum soluble Fas in the syndrome of hemolysis, elevated liver enzymes, and low platelets",
abstract = "OBJECTIVE: To assess whether serum levels of soluble Fas and soluble Fas ligand are altered in the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). METHODS: Serum samples from 22 pregnant women diagnosed with HELLP syndrome were compared with sera from 37 healthy women with noncomplicated singleton pregnancies. Serum levels of soluble Fas and soluble Fas ligands were determined by enzyme immunoassay. Student t, χ2, Pearson's correlation coefficient, and multiple regression tests were used for statistical analyses. RESULTS: Both soluble Fas and soluble Fas ligand were detected in the sera of normal pregnancies as well as in those with HELLP syndrome. The mean serum level of soluble Fas was significantly higher in women with HELLP syndrome than in healthy gravidas (10.75 ± 0.93 versus 5.81 ± 0.37 U/mL, P < .001). However, there was no significant difference in mean serum soluble Fas ligand levels of the two groups (0.60 ± 0.06 compared with 0.50 ± 0.22 ng/mL, P = .23). In women with HELLP syndrome, there were no significant correlations between serum levels of soluble Fas or soluble Fas ligand with liver transaminases (aspartate and alanine aminotransferase) and platelet count. CONCLUSION: Serum levels of soluble Fas, but not soluble Fas ligand, are significantly higher in women with HELLP syndrome than healthy gravidas. The source of elevated serum levels of soluble Fas in HELLP syndrome remains to be determined.",
author = "Hassan Harirah and Donia, {Sahar E.} and Hsu, {Chaur Dong}",
year = "2001",
doi = "10.1016/S0029-7844(01)01415-6",
language = "English (US)",
volume = "98",
pages = "295--298",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Serum soluble Fas in the syndrome of hemolysis, elevated liver enzymes, and low platelets

AU - Harirah, Hassan

AU - Donia, Sahar E.

AU - Hsu, Chaur Dong

PY - 2001

Y1 - 2001

N2 - OBJECTIVE: To assess whether serum levels of soluble Fas and soluble Fas ligand are altered in the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). METHODS: Serum samples from 22 pregnant women diagnosed with HELLP syndrome were compared with sera from 37 healthy women with noncomplicated singleton pregnancies. Serum levels of soluble Fas and soluble Fas ligands were determined by enzyme immunoassay. Student t, χ2, Pearson's correlation coefficient, and multiple regression tests were used for statistical analyses. RESULTS: Both soluble Fas and soluble Fas ligand were detected in the sera of normal pregnancies as well as in those with HELLP syndrome. The mean serum level of soluble Fas was significantly higher in women with HELLP syndrome than in healthy gravidas (10.75 ± 0.93 versus 5.81 ± 0.37 U/mL, P < .001). However, there was no significant difference in mean serum soluble Fas ligand levels of the two groups (0.60 ± 0.06 compared with 0.50 ± 0.22 ng/mL, P = .23). In women with HELLP syndrome, there were no significant correlations between serum levels of soluble Fas or soluble Fas ligand with liver transaminases (aspartate and alanine aminotransferase) and platelet count. CONCLUSION: Serum levels of soluble Fas, but not soluble Fas ligand, are significantly higher in women with HELLP syndrome than healthy gravidas. The source of elevated serum levels of soluble Fas in HELLP syndrome remains to be determined.

AB - OBJECTIVE: To assess whether serum levels of soluble Fas and soluble Fas ligand are altered in the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP). METHODS: Serum samples from 22 pregnant women diagnosed with HELLP syndrome were compared with sera from 37 healthy women with noncomplicated singleton pregnancies. Serum levels of soluble Fas and soluble Fas ligands were determined by enzyme immunoassay. Student t, χ2, Pearson's correlation coefficient, and multiple regression tests were used for statistical analyses. RESULTS: Both soluble Fas and soluble Fas ligand were detected in the sera of normal pregnancies as well as in those with HELLP syndrome. The mean serum level of soluble Fas was significantly higher in women with HELLP syndrome than in healthy gravidas (10.75 ± 0.93 versus 5.81 ± 0.37 U/mL, P < .001). However, there was no significant difference in mean serum soluble Fas ligand levels of the two groups (0.60 ± 0.06 compared with 0.50 ± 0.22 ng/mL, P = .23). In women with HELLP syndrome, there were no significant correlations between serum levels of soluble Fas or soluble Fas ligand with liver transaminases (aspartate and alanine aminotransferase) and platelet count. CONCLUSION: Serum levels of soluble Fas, but not soluble Fas ligand, are significantly higher in women with HELLP syndrome than healthy gravidas. The source of elevated serum levels of soluble Fas in HELLP syndrome remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=0034886773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034886773&partnerID=8YFLogxK

U2 - 10.1016/S0029-7844(01)01415-6

DO - 10.1016/S0029-7844(01)01415-6

M3 - Article

C2 - 11506848

AN - SCOPUS:0034886773

VL - 98

SP - 295

EP - 298

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 2

ER -